The objective of this study was to prospectively evaluate dose-intensified hypofractionated stereotactic body radiation therapy (SBRT) in patients with painful spinal metastases in a multicenter, single-arm, phase 2 study. METHODS: Patients with 2 or fewer distinct, noncontiguous, painful, mechanically stable, unirradiated spinal metastases from a solid tumor with a Karnofsky performance status 60 were eligible. Patients with a long (Mizumoto score 4) or intermediate overall survival expectancy (Mizumoto score 5 5-9) received 48.5 Gy in 10 fractions or 35 Gy in 5 fractions, respectively, with SBRT. The primary outcome was the overall (complete and partial) pain response as measured with international consensus guidelines 3 months after SBRT. RESULTS: There were 57 patients enrolled between 2012 and 2015, and 54 of these patients with 60 painful vertebral metastases were analyzed. The 3-month pain response was evaluated in 42 patients (47 lesions). An overall pain response was observed in 41 lesions (87%), and the pain response remained stable for at least 12 months. The mean maximum pain scores on a visual analogue scale significantly improved from the baseline of 6.1 (standard deviation, 2.5) to 2.0 (standard deviation, 2.3) 3 months after treatment (P < .001). The 5-level EuroQol 5-Dimension Questionnaire quality-of-life (QOL) dimensions (self-reported mobility, usual activities, and pain/discomfort) significantly improved from the baseline to 3 months after treatment. The 12-month overall survival and local control rates were 61.4% (95% confidence interval [CI], 48%-74.8%) and 85.9% (95% CI, 76.7%-95%), respectively. Grade 3 toxicity was limited to acute pain in 1 patient (2%). No patient experienced radiation-induced myelopathy. Six patients (11%) developed progressive vertebral compression fractures (VCFs), and 8 patients (15%) developed new VCFs. CONCLUSIONS: Dose-intensified SBRT achieved durable local metastasis control and resulted in pronounced and long-term pain responses and improved QOL. Cancer 2018;124:2001-9. V C 2018 American Cancer Society.
INTRODUCTION
Radiation therapy is recognized as an effective palliative treatment for painful spinal metastases without spinal instability. Conventional multifraction or single-fraction radiation therapy results in overall and complete pain responses in approximately 70% and 30% of patients, respectively, 1,2 with an average pain-response duration of 3 to 7 months. 2, 3 This limited short-term pain response may not be sufficient for subsets of patients whose lifespan extends from several months to several years because of improvements in diagnostics, systemic treatment, and supportive care. 4, 5 With longer survival, these patients are at higher risk for pain recurrence due to metastatic tumor progression and for complications of spinal instability and metastatic spinal cord compression. Such patients may require different treatment strategies providing durable metastasis control as a basis for durable symptom control and the prevention of complications.
Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), using image-guided delivery of higher radiation doses to spinal metastases and providing improved sparing of the adjacent organs at risk, resulted in promising safety and efficacy in nonrandomized clinical trials. 6 Long-lasting spinal-metastasis local control and subsequent pain control after SRS/SBRT were reported for 12 to 24 months, whereas retreatment rates did not exceed 0% to 15%. Most SBRT studies reported local control as the primary outcome, whereas prospective data on pain relief with SBRT are scarce. [7] [8] [9] [10] There are also uncertainties about which patients with painful spinal metastases would benefit the most from SBRT and whether patients with epidural disease are candidates for SBRT. To investigate these questions, we conducted a prospective, multicenter, nonrandomized, single-arm, phase 2 study of dose-intensified hypofractionated SBRT for painful spinal metastases, regardless of epidural and paravertebral involvement, in patients with an intermediate or long overall survival expectancy. Herein we report the treatment outcome of this prospective clinical trial. The main goal was to determine the overall (complete and partial) pain response to SBRT. We also report on spinal-metastasis local control, survival, treatment-induced toxicity, and quality of life (QOL).
MATERIALS AND METHODS

Study Patients
This prospective, multicenter, phase 2, nonrandomized clinical trial was approved by local ethics committees, was registered at ClinicalTrials.gov (NCT01594892), and was conducted in accordance with the ethical standards set forth by the Declaration of Helsinki. 11 Patients were eligible if they were 18 years old or older with a histologically proven diagnosis of a solid tumor (excluding multiple myeloma, small cell lung cancer, and lymphoma) and had a maximum of 2 distinct, noncontiguous, painful or pain-free (with pain medication) spinal metastases, a Karnofsky performance status 60, and a modified (hypercalcemia was not scored) prognostic Mizumoto score for life expectancy 9 (this excluded patients with a short overall survival expectancy). 12 Patients were ineligible in case of spinal instability, the involvement of more than 3 continuous vertebral levels, progressive neurological symptoms/deficits, or previous radiation therapy at the treated site. Patients after stabilization or decompressive surgery who were receiving bisphosphonates and/or systemic treatment were not excluded.
SBRT Treatment Planning and Delivery
Treatment was performed as described previously. 13 All patients underwent treatment-planning computed tomography (CT) performed in the treatment position; BodyFIX immobilization (Elekta, Stockholm, Sweden) was used for 46 patients (85%), and another immobilization device (a head mask) was used for 8 patients (15%). The gross tumor volume was delineated on planning CT scans with coregistered magnetic resonance tomography whenever available (54 of 60 lesions [90%]). The clinical target volume was defined as all macroscopically involved elements-body, pedicles, transverse process, and spinous process-of the involved vertebra. The high-dose planning target volume (PTV) was generated with an isotropic 2-mm expansion of the clinical target volume excluding the spinal cord. The low-dose PTV was defined as the entire vertebrae of the involved levels. The spinal cord itself, cauda equina, pharynx, esophagus, lungs, kidneys, and bowel were delineated as organs at risk. The spinal cord and cauda equina were expanded by a 1-to 2-mm margin to obtain the corresponding planning at-risk volumes. The dose prescription involved 2 dose levels delivered simultaneously (simultaneous integrated boost). Treatment-planning objectives for organs at risk were reported previously. 13 Patients with a long life expectancy (ie, patients with a Mizumoto score of 0-4) were treated with 10 fractions (total dose for the high-dose PTV, 48. 10 , 28 Gy]). SBRT was delivered with a 6-to 18-MV linear accelerator with onboard imaging cone-beam CT using volumetric modulated arc therapy or step-and-shoot intensity-modulated radiation therapy.
Endpoints
The primary endpoint of the study was pain improvement of 2 or more points on a visual analogue scale (VAS) 3 months after treatment at the site of the treated lesion (ie, the overall pain response [the sum of the complete and partial responses] measured according to international consensus guidelines).
14 The worst and average pain in the past week was scored on the 0 to 10 VAS, with 0 representing no pain and 10 representing the severest pain. Patient-reported pain and pain medication as the daily oral morphine equivalent were assessed at the baseline before SBRT, on the last day of SBRT treatment, and thereafter at 1, 2, 3, 4, 5, and 6 weeks and 3, 6, 9, and 12 months after SBRT. A complete response was defined as a VAS pain score of 0 at the treated site with no concomitant increase in the daily oral morphine equivalent. A partial response was defined as a pain score reduction of 2 or more at the treated site without an increase in daily oral morphine equivalent consumption or as no increase in pain and a reduction of 25% or more in daily oral morphine equivalent consumption. 9 Pain progression was defined as an increase in the pain score of 2 or more at the treated site with stable oral morphine equivalent Original Article consumption or as a pain score that was stable or 1 point above the baseline with an increase of 25% or more in daily oral morphine equivalent consumption. In the case of 2 treated lesions, pain was scored individually for each site.
Secondary endpoints included the incidence of acute toxicities (6 weeks after treatment) and late toxicities (3 months after treatment) graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0), neurological assessments, spinal-metastasis local control, overall survival, and patient-reported health-related QOL. A vertebral compression fracture (VCF) was defined as an imagingdetermined decrease in the height of the treated vertebra, regardless of the presence of symptoms. Spinal-metastasis local control was defined as no radiological sign of tumor progression at the site of the treated spinal metastasis; overall survival was defined as death from any cause. QOL was measured with the 5-level EuroQol 5-Dimension Questionnaire (EQ-5D-5L) 15 at the baseline and 3 months after treatment. The EQ-5D-5L was used together with a 0-to 100-point VAS for rating the overall health status (EQ VAS). A physical, neurological, and radiological examination of patients was performed at the baseline and during follow-up.
Statistical Analysis
We hypothesized that the overall pain response 3 months after SBRT would improve from 45% with conventionally fractionated radiation therapy to 75% with imageguided, hypofractionated SBRT. Sample size calculations with a 5% type I error and a power of 90% resulted overall in 54 patients and SBRT treatments. With a 10% dropout rate, the total number of patients and SBRT treatments was 60. The study was not designed for a statistical comparison of the 2 SBRT fractionation schedules.
We used descriptive statistics to describe demographic and clinical characteristics of the patients, treated lesions, SBRT dose-volume indices, QOL dimensions, and the EQ VAS. The paired t test (2-tailed) was used to test for differences in the baseline and 3-month posttreatment pain scores, in pain scores for patients before and after they developed VCFs, in the use of opioids and nonopioids, and in the EQ-5D-5L QOL. The Wilcoxon rank-sum test was used to compare posttreatment painresponse rates in patients with and without VCFs. Spinalmetastasis local control and overall survival were calculated with the Kaplan-Meier method as well as associated 95% confidence intervals (CIs). Patients were censored at the date of death or at the date of their last known followup, whichever came first. Statistical significance was evaluated at P < .05, and the analysis was performed with the BrightStat software package (version 1.2.20).
RESULTS
Between March 2012 and July 2015, 57 patients were enrolled, but 3 patients were excluded from the analysis because of missing information for the baseline pain score and pain medication; this resulted in 54 patients with 60 painful metastatic lesions. Baseline demographics and metastasis characteristics are presented in Table 1 . Six patients had 2 separate lesions treated synchronously (n 5 2) or sequentially (n 5 4). Thirty of the 54 patients (56%) had oligometastatic disease (5 distant metastases), and 35 patients (65%) were free of visceral metastases. All patients reported pain (Table 1 ). Before treatment, 18 patients (33%) and 35 patients (65%) used opioids and nonopioid pain medication, respectively. Forty-two lesions were osteolytic (70%), 7 were osteoblastic (12%), and 11 were mixed (18%); 43 lesions (72%) had an epidural tumor component with a Bilsky score > 0. Fourteen patients (26%) had already presented with a VCF at enrollment. Twenty-four patients (44%) were treated with 5 SBRT fractions. The remaining 30 patients (56%) were treated with 10 SBRT fractions, and 4 of these patients had a Mizumoto score of 5 to 8, which was considered to be a minor violation of the study protocol. All patients completed the treatment as prescribed.
Pain Response
Pain scores at the baseline before SBRT were available for 60 lesions, and the pain score 3 months after SBRT was available for 47 lesions (78.3%); the reason for the loss of patients to follow-up was the progression of metastatic disease with a worsening overall health status or death. An overall pain response was achieved for 41 of 47 lesions (87%) 3 months after treatment, for 19 of 21 lesions (91%) after 5-fraction SBRT, and for 22 of 26 lesions (85%) after 10-fraction SBRT. There was no difference in the pain responses of patients with an epidural tumor component and patients without an epidural tumor component (P 5 .5). At the time of the primary endpoint, 14 lesions (30%) showed a complete pain response, which remained constant until 12 months after treatment (Fig.  1 ). Before treatment, 18 patients with 19 lesions used opioids as pain medication, and 12 of these patients with 13 lesions stopped using opioids until 3 months after SBRT. During follow-up, 5 patients with 5 lesions started with opioid medication. The difference in the rates of opioid medication at the baseline and 3 months after SBRT was not statistically significant (P < .41). There was a significant reduction in the use of nonopioid pain medication: 35 patients with 35 lesions at the baseline versus 17 patients with 17 lesions 3 months after SBRT (P < .01).
The mean maximum and average VAS pain scores at the treated site significantly improved from 6.1 and 4.3 at the baseline to 2.0 and 1.7, respectively, 3 months after SBRT (P < .001; Table 2 and Fig. 2A,B) . A rapid pain response was observed for lesions with severe pretreatment pain: Before treatment, there were 31 painful lesions (52%) with a VAS score of 7 to 10. This proportion dropped to 20% at the end of SBRT and remained constant at approximately 10% during the whole duration of followup (Fig. 1) .
Local Control and Overall Survival
At the time of the analysis, 25 of the 54 patients (46%) were still alive. The median follow-up time was 12 months (range, 1-47 months) for all patients and 19 months (range, 5-47 months) for living patients. The actuarial estimate of local control of all 60 lesions was 85.9% (95% CI, 76.7%-95%) at 12 months (Fig. 3A) . The rates of local control of lesions treated with 10 and 5 fractions were 93% (95% CI, 83.6%-100%) and 78.1% (95% CI, 62.5%-93.6%), respectively, at 12 months.
The actuarial estimate of overall survival for all patients was 61.4% at 12 months (95% CI, 48%-74.8%; Fig. 3B ). Patients selected for 10 fractions had significantly better overall survival at 12 months than patients selected for 5 fractions: 76.4% (95% CI, 61%-91.7%) versus 40.6% (95% CI, 19.2%-62.1%; P 5 .008). The median overall survival of all patients, patients treated with 10 fractions, and patients treated with 5 fractions was 19, 38, and 9 months, respectively.
Toxicity
There was no grade 4 or higher toxicity, and grade 3 toxicity was limited to 1 patient with acute pain (Table 3) . Only 4 patients (8%) developed grade 2 acute toxicity. Late toxicity (3 months after SBRT) was evaluated in 38 patients, and only 1 patient suffered from grade 1 skin induration. No patient developed radiation-induced myelopathy. Among the 54 patients, 6 (11%) and 8 (15%) developed progressive and new VCFs, respectively; the median time to the development or progression of a VCF was identical at 2 months (range, 0.4-40 months) after SBRT (Table 4) . Nine (17%) and 5 fractures (9%) developed after 10-and 5-fraction SBRT, respectively. For patients with progressive or new VCFs, the mean maximum VAS pain score was 2.6 (standard deviation, 3.2) at the last follow-up before the VCF diagnosis and 3.2 (standard deviation, 3.5) at the first follow-up with a diagnosis of VCF (P < .01). There was no difference in 3-month posttreatment pain-response rates in patients with and without VCFs. The neurological status did not change before and after the diagnosis of a VCF. Walking ability, sensory status, defecation, and voiding were preserved in all but 1 patient with progressive VCF, who died within 3 months Abbreviations: C, cervical; L, lumbar; S, sacral; T, thoracic; VCF, vertebral compression fracture.
of SBRT because of disease progression. Two patients with VCFs underwent subsequent stabilization (n 5 1) and decompression surgery (n 5 1); no patient was reirradiated during follow-up.
QOL
Thirty-three patients (61%) completed the EQ-5D-5L QOL questionnaire at the baseline and at the 3-month follow-up. The health profiles of all dimensions were stable or improved (Supporting Table 1 ). The mean QOL significantly improved from the baseline of 2.3 (standard deviation, 1.1) to 1.8 (standard deviation, 0.9) 3 months after SBRT for self-reported mobility (P < .05), from 2.9 (standard deviation, 1.3) to 2.4 (standard deviation, 1.1) for usual activities (P < .05), and from 3.0 (standard deviation, 0.8) to 2.3 (standard deviation, 0.9) for pain/ discomfort (P 5 .001; Fig. 4 ). The EQ VAS score improved from a mean of 51 (standard deviation, 21.7) to 61.3 (standard deviation, 19.2; P < .05).
DISCUSSION
Hypofractionated SBRT achieved an overall painresponse rate of 87% (complete response, 30%; partial response, 57%) 3 months after treatment, which met the primary endpoint of our study. The pain response developed rapidly and was durable for at least 12 months as the result of a long-term, imaging-verified local metastasis control rate of 85.9% 12 months after treatment. In addition, the pain response was associated with an approximately 50% reduction of opioid and nonopioid pain medication use. Our results compare favorably with those of conventional radiation therapy, with which a pain response is achieved in 60% to 70% of patients, but the duration of the pain response is limited to 3 to 7 months.
1-3
Although short-term palliation with conventional radiotherapy may be sufficient for patients with a poor prognosis, patients with a good overall survival prognosis may benefit from durable pain control achieved with SBRT. In our study, the Mizumoto score performed well for selecting patients with improved overall survival expectancy, who might benefit the most from SBRT. Whether dose-intensified hypofractionated SBRT contributed to this favorable overall survival is unknown but possible because 56% of our patients presented with oligometastatic disease. Moreover, hypofractionated treatment allowed the inclusion of patients with an epidural disease component, which is frequently a contraindication for single-fraction radiosurgery (eg, the Radiation Therapy Oncology Group 0631 study). In fact, the majority of the lesions showed epidural disease, and 43% showed spinal cord compression (Bilsky score 2): the outcomes were identical to those for patients without epidural disease. Even though it was first described in 1995, 16 only a few trials, all phase 1 or 2, have prospectively evaluated SBRT for spinal metastases. Wang et al 10 reported a phase 1/2 study of spinal SBRT delivering 27 to 30 Gy in 3 fractions. A heterogeneous cohort of 149 patients was evaluated, with 53% receiving re-irradiation, and 65% of the patients were without pain or had only mild pain at the baseline as assessed with the Brief Pain Inventory. The proportion of patients with moderate or severe pain decreased from 34% at the baseline to 22% at 3 months. In another phase 1/2 study, 61 previously unirradiated patients received 16 to 24 Gy in single-fraction SRS. 8 The proportion of patients without pain on the Brief Pain Inventory nonsignificantly increased from 13 of 61 at the baseline to 18 of 61 at 3 to 6 months. Unfortunately, a more detailed pain response was not assessed. Amdur et al 9 reported a phase 2 study of single 15-Gy fraction SRS in 25 patients, of whom 12 were retreated. Of 14 patients with a pretreatment pain score of 2 to 10 on a pain scoring scale, 43% reported some degree of pain relief, and 3 of the 14 patients achieved a complete pain response. Overall, the pain-response rate appears higher in our study in comparison with the other SBRT trials; however, different inclusion criteria, including preceding (local and systemic) treatments and different instruments used for the assessment of the pain response (the Brief Pain Inventory, 8, 10 a pain scoring scale, 9 or the VAS in our study), that is, different definitions of pain response, make direct comparisons difficult. The Radiation Therapy Oncology Group 0631 study, comparing singlefraction SRS/SBRT against single-fraction conventional radiation therapy, has finished recruitment, and its results are eagerly awaited.
A rapid and durable pain response was associated with improved QOL: significant improvements were observed in the EQ-5D-5L dimensions of self-reported mobility, usual activities, pain/discomfort, and overall health status 3 months after treatment. The small number of patients available for the QOL assessment did not allow us to correlate changes in QOL dimensions with the pain response and other pain and treatment characteristics. Further investigation is warranted.
SBRT was well tolerated with only minimal and self-limiting toxicity and no radiation-induced myelopathy at the sufficiently long median follow-up of 19 months. These results agree with prospective trials and large retrospective studies of spinal SBRT. 7, 17, 18 The proportion of our patients developing VCFs was 26%, which is within the range reported in the SBRT literature, [19] [20] [21] although after conventional radiation therapy, approximately 3% of patients develop VCFs. 2 Interpreting VCFs in our study requires caution for several reasons. First, every reduction in the craniocaudal height of a treated vertebra was scored as a VCF independently of whether the patient was symptomatic or not. In fact, the development of a VCF was associated only with minimally increased pain and required surgical stabilization in only 2 patients (3.7%). Consequently, the proportion of patients requiring an intervention for VCFs appears to be not increased in comparison with conventional radiation therapy. Second, our patient cohort was characterized by an accumulation of well-established risk factors for VCFs, 19 including solitary spinal metastases with improved overall survival (54 of 60 lesions), osteolytic lesions (42 of 60 lesions), and a high rate of preexisting VCFs (14 of 54 patients). Developing a predictive model for VCFs would help in identifying patients who might benefit from early stabilization procedures.
A potential limitation of our trial is its design as a single-arm phase 2 study with a small sample size and without a control group of conventional radiation therapy patients. In addition, 2 different SBRT fractionations were used, and our study was not designed for a comparison of the 2 arms. Finally, follow-up was reasonable for a metastatic patient cohort with a median of 19 months; however, this may still be too short for an evaluation of very late and rare toxicities.
In conclusion, this prospective study demonstrated a rapid and durable pain response combined with improved QOL with dose-intensified hypofractionated SBRT as the first-line treatment for painful spinal metastases. Although the results of randomized clinical trials are pending, this treatment should be discussed for patients with a longer overall survival expectancy.
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